The value of serum CA19-9 in predicting primary sclerosing cholangitis in patients with ulcerative colitis
The value of serum CA19-9 in predicting primary sclerosing cholangitis in patients with ulcerative colitis
نویسندگان: زینب نیک نیاز , کوروش مسندی شیرازی , آرمان مسندی شیرازی نژاد , یاسمن حسین زاده , زهرا نورپناه
کلمات کلیدی: CA19-9, primary sclerosing cholangitis, ulcerative colitis
نشریه: 0 , 0 , 0 , 2019
| نویسنده ثبت کننده مقاله |
زینب نیک نیاز |
| مرحله جاری مقاله |
تایید نهایی |
| دانشکده/مرکز مربوطه |
بیماری های گوارش و کبد |
| کد مقاله |
71362 |
| عنوان فارسی مقاله |
The value of serum CA19-9 in predicting primary sclerosing cholangitis in patients with ulcerative colitis |
| عنوان لاتین مقاله |
The value of serum CA19-9 in predicting primary sclerosing cholangitis in patients with ulcerative colitis |
| ناشر |
5 |
| آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ |
خیر |
| عنوان نشریه (خارج از لیست فوق) |
advances in digestive medicine |
| نوع مقاله |
Original Article |
| نحوه ایندکس شدن مقاله |
ایندکس شده سطح یک – ISI - Web of Science |
| آدرس لینک مقاله/ همایش در شبکه اینترنت |
|
| In the present study, we postulated that using CA19-9 in inflammatory bowel disease
(IBD) patients may be a useful method for the screening of primary sclerosing cholangitis (PSC). Considering the presence of other extraintestinal manifestations (EIMs)
in IBD such as arthritis that may associate with the elevated level of CA19-9, in the
present study we aimed to compare the CA19-9 level in ulcerative colitis (UC) patients
with PSC or other EIMs and also evaluate the value of CA19-9 in the detection of
PSC in UC patients. In the present cross-sectional study, 192 patients with UC were
selected. EIMs were diagnosed based on patients recall and after a thorough physical
examination. PSC was diagnosed by magnetic resonance cholangiopancreatography
by expert gastroenterologist and radiologist. Serum level of CA19-9 was measured
using chemiluminescent enzyme immunometric assay. About 6.77% of participants
had PSC and 24.47% of them had other EIMs. The results showed that the CA19-9
level in patients with PSC (median [interquartile range (IQR)]: 93 [10-125]) was significantly higher than that of patients diagnosed with other EIMs (median [IQR]:
11 [6-17.30]) or with no EIMs (median [IQR]: 7.15 [4.82-11.00]). CA19-9 value of
>75 U/mL could predict PSC by the sensitivity of 69% and specificity of 99% with an
area under the ROC curve (AUC) of 0.83 in UC patients and alkaline phosphatase
(ALP) > 299.5 could predict PSC with a sensitivity of 100% and a specificity of 99%
and AUC of 0.99. In addition, 23.07% of PSC patients had CA19-9 level of >129 U/
mL. According to the results, ALP had higher sensitivity and specificity for the screening of PSC compared to CA19-9 in UC patients. Moreover, 23.07% of PSC patients
had CA19-9 level of >129 U/mL. So it could be concluded that cut-off of >129 U/mL
may not be an accurate cut-off for the diagnosis of CCA in IBD patients. |
| نام فایل |
تاریخ درج فایل |
اندازه فایل |
دانلود |
| ca19 pac.pdf | 1398/12/14 | 774280 | دانلود |